Pure BIOSCIENCE, Inc. (PURE) intrinsic value & 10-year financials
Pure BIOSCIENCE, Inc. (PURE) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 6.1% a year to $2.2M, with an average return on invested capital of -137.6%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.07
- Market cap
- $7.8M
- Revenue (FY2025)
- $2.2M
- Revenue growth (10-yr CAGR)
- 6.1%
- ROIC (10-yr avg)
- -137.6%
- Free cash flow (FY2025)
- —
PURE 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $2.2M | -$2.4M | -$0.02 | — | -103.2% | 56.9% |
| FY2024 | $2.0M | -$3.4M | -$0.03 | — | -162.6% | 246.2% |
| FY2023 | $1.9M | -$4.0M | -$0.04 | -$3.3M | -210.1% | -188.6% |
| FY2022 | $1.9M | -$3.5M | -$0.04 | -$2.5M | -201.0% | -102.8% |
| FY2021 | $3.9M | -$2.3M | -$0.03 | -$1.7M | -58.8% | -56.8% |
| FY2020 | $6.9M | $4.0K | $0.00 | $611.0K | 0.1% | 0.1% |
| FY2019 | $1.9M | -$6.6M | -$0.09 | -$3.0M | -292.8% | -452.4% |
| FY2018 | $1.8M | -$7.4M | — | -$3.9M | -397.0% | -547.8% |
| FY2017 | $1.8M | -$6.3M | — | -$4.8M | -328.1% | -190.3% |
| FY2016 | $1.3M | -$14.4M | — | -$5.4M | -547.5% | -140.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PURE BIOSCIENCE, INC. has demonstrated mature, steady growth, with revenue compounding at 6.1% annually over the past decade.
PURE BIOSCIENCE, INC. has historically struggled to out-earn its cost of capital, averaging just -25.4% ROIC.
PURE BIOSCIENCE, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PURE BIOSCIENCE, INC. is modeled at 6.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.36 per share.